vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and ServisFirst Bancshares, Inc. (SFBS). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $159.0M, roughly 1.1× ServisFirst Bancshares, Inc.). ServisFirst Bancshares, Inc. runs the higher net margin — 52.2% vs 1.6%, a 50.5% gap on every dollar of revenue. Over the past eight quarters, ServisFirst Bancshares, Inc.'s revenue compounded faster (17.7% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ServisFirst Bancshares, Inc. is a U.S.-based bank holding company operating full-service banking locations primarily across the Southeastern United States. It offers a full suite of commercial banking, consumer banking, wealth management, and mortgage lending services to small and medium-sized businesses, professional clients, and individual consumers.
PCRX vs SFBS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $159.0M |
| Net Profit | $2.9M | $83.0M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | — |
| Net Margin | 1.6% | 52.2% |
| Revenue YoY | 5.0% | — |
| Net Profit YoY | — | 31.2% |
| EPS (diluted) | $0.07 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $159.0M | ||
| Q4 25 | $196.9M | $162.2M | ||
| Q3 25 | $179.5M | $136.3M | ||
| Q2 25 | $181.1M | $132.1M | ||
| Q1 25 | $168.9M | $131.8M | ||
| Q4 24 | $187.3M | $131.9M | ||
| Q3 24 | $168.6M | $123.7M | ||
| Q2 24 | $178.0M | $114.8M |
| Q1 26 | $2.9M | $83.0M | ||
| Q4 25 | — | $86.4M | ||
| Q3 25 | $5.4M | $65.6M | ||
| Q2 25 | $-4.8M | $61.4M | ||
| Q1 25 | $4.8M | $63.2M | ||
| Q4 24 | — | $65.2M | ||
| Q3 24 | $-143.5M | $59.9M | ||
| Q2 24 | $18.9M | $52.1M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 66.3% | ||
| Q3 25 | 3.5% | 57.8% | ||
| Q2 25 | 4.7% | 58.0% | ||
| Q1 25 | 1.2% | 60.0% | ||
| Q4 24 | 13.2% | 60.2% | ||
| Q3 24 | -82.8% | 58.5% | ||
| Q2 24 | 15.9% | 58.0% |
| Q1 26 | 1.6% | 52.2% | ||
| Q4 25 | — | 59.0% | ||
| Q3 25 | 3.0% | 48.1% | ||
| Q2 25 | -2.7% | 46.5% | ||
| Q1 25 | 2.8% | 48.0% | ||
| Q4 24 | — | 52.9% | ||
| Q3 24 | -85.1% | 48.4% | ||
| Q2 24 | 10.6% | 45.4% |
| Q1 26 | $0.07 | $1.52 | ||
| Q4 25 | $0.05 | $1.58 | ||
| Q3 25 | $0.12 | $1.20 | ||
| Q2 25 | $-0.11 | $1.12 | ||
| Q1 25 | $0.10 | $1.16 | ||
| Q4 24 | $0.38 | $1.19 | ||
| Q3 24 | $-3.11 | $1.10 | ||
| Q2 24 | $0.39 | $0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $1.8B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $1.9B |
| Total Assets | $1.2B | $18.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $1.8B | ||
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | $1.9B | ||
| Q4 25 | $693.1M | $1.8B | ||
| Q3 25 | $727.2M | $1.8B | ||
| Q2 25 | $757.8M | $1.7B | ||
| Q1 25 | $798.5M | $1.7B | ||
| Q4 24 | $778.3M | $1.6B | ||
| Q3 24 | $749.6M | $1.6B | ||
| Q2 24 | $879.3M | $1.5B |
| Q1 26 | $1.2B | $18.2B | ||
| Q4 25 | $1.3B | $17.7B | ||
| Q3 25 | $1.3B | $17.6B | ||
| Q2 25 | $1.5B | $17.4B | ||
| Q1 25 | $1.6B | $18.6B | ||
| Q4 24 | $1.6B | $17.4B | ||
| Q3 24 | $1.5B | $16.4B | ||
| Q2 24 | $1.6B | $16.0B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SFBS
| Net Interest Income | $148.1M | 93% |
| Noninterest Income | $10.8M | 7% |
